[go: up one dir, main page]

CN1293665A - 新化合物及其用作阳性ampa受体调节剂 - Google Patents

新化合物及其用作阳性ampa受体调节剂 Download PDF

Info

Publication number
CN1293665A
CN1293665A CN99804196A CN99804196A CN1293665A CN 1293665 A CN1293665 A CN 1293665A CN 99804196 A CN99804196 A CN 99804196A CN 99804196 A CN99804196 A CN 99804196A CN 1293665 A CN1293665 A CN 1293665A
Authority
CN
China
Prior art keywords
alkyl
aryl
arbitrarily
dioxide
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99804196A
Other languages
English (en)
Chinese (zh)
Inventor
A·H·高里艾夫
M·拉森
T·瓦明
C·马西森
T·H·简森
J·西尔－克鲁格
G·M·奥尔森
E·O·尼尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Publication of CN1293665A publication Critical patent/CN1293665A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
    • C07D285/28—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN99804196A 1998-02-18 1999-02-18 新化合物及其用作阳性ampa受体调节剂 Pending CN1293665A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK22698 1998-02-18
DK0226/98 1998-02-18

Publications (1)

Publication Number Publication Date
CN1293665A true CN1293665A (zh) 2001-05-02

Family

ID=8091151

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99804196A Pending CN1293665A (zh) 1998-02-18 1999-02-18 新化合物及其用作阳性ampa受体调节剂

Country Status (17)

Country Link
EP (1) EP1071426A2 (is)
JP (1) JP2002504481A (is)
CN (1) CN1293665A (is)
AU (1) AU751384B2 (is)
CA (1) CA2320354A1 (is)
EE (1) EE200000468A (is)
HU (1) HUP0101280A3 (is)
IL (1) IL137720A0 (is)
IS (1) IS5581A (is)
NO (1) NO20004121L (is)
NZ (1) NZ506251A (is)
PL (1) PL342843A1 (is)
RU (1) RU2214405C2 (is)
SK (1) SK11892000A3 (is)
TR (1) TR200002427T2 (is)
WO (1) WO1999042456A2 (is)
ZA (1) ZA991301B (is)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1308317C (zh) * 2004-01-26 2007-04-04 瑟维尔实验室 新的氟化苯并噻二嗪化合物，它们的制备方法和含有它们的药物组合物
CN102361860A (zh) * 2009-03-20 2012-02-22 瑟维尔实验室 用作ampa和nmda受体调节剂的苯并硫杂二氮杂*衍生物
CN102958919A (zh) * 2010-07-02 2013-03-06 霍夫曼-拉罗奇有限公司 新的四氢喹啉衍生物
CN102977054A (zh) * 2012-12-12 2013-03-20 中国药科大学 一类选择性α2A受体激动剂的治疗阿尔茨海默病用途
CN103153973A (zh) * 2010-09-16 2013-06-12 瑟维尔实验室 二氢苯并氧硫氮杂*衍生物、其制备方法、包含此类化合物的药用组合物以及它们作为ampa受体调节剂的用途
CN103319381A (zh) * 2013-06-14 2013-09-25 湖州康企药业有限公司 一种高纯度精磺胺的制备方法
CN105294599A (zh) * 2015-09-17 2016-02-03 三峡大学 一种噻二嗪类化合物及其不对称的合成方法
CN106946920A (zh) * 2017-04-05 2017-07-14 泰力特医药（湖北）有限公司 一种4‑氨基苯硼酸衍生物的制备方法
CN111018750A (zh) * 2019-12-19 2020-04-17 苏州诚和医药化学有限公司 一种2,3-二甲氧基-5-磺酰胺基苯甲酸的制备新方法
CN111100042A (zh) * 2019-11-18 2020-05-05 苏州诚和医药化学有限公司 一种2-甲氧基-5-磺酰胺基苯甲酸的制备方法
WO2020253860A1 (zh) * 2019-06-21 2020-12-24 江苏豪森药业集团有限公司 芳基磷氧化物类衍生物抑制剂、其制备方法和应用

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671200B2 (en) 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
DE10004572A1 (de) 2000-02-02 2001-08-09 Boehringer Ingelheim Pharma Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
FR2812291B1 (fr) * 2000-07-28 2002-12-13 Adir Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN1314351A (zh) * 2001-03-22 2001-09-26 刘志红 喹唑啉酮合成方法及具有抗癌作用的一类喹唑啉酮化合物
TWI232863B (en) * 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
HUP0400196A3 (en) 2001-06-14 2007-05-02 Organon Nv (pyrido/thieno)[f]oxazepin-5-one derivatives, their use and pharmaceutical compositions containing them
US7199118B2 (en) 2001-10-10 2007-04-03 Neurosearch A/S Benzothiazine derivatives, their preparation and use
UA79940C2 (en) * 2001-11-26 2007-08-10 Cortex Pharma Inc Carbonylbenzoxazine compounds for enhancing of glutamatergic synaptic responses
FR2833950B1 (fr) * 2001-12-21 2005-12-16 Servier Lab Nouveaux derives de benzothiazine et de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2833956B1 (fr) * 2001-12-21 2004-01-30 Servier Lab Nouveaux derives de benzothiazine et de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2833955B1 (fr) * 2001-12-21 2004-01-30 Servier Lab Nouveaux derives de benzothiazine et de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2854634B1 (fr) * 2003-05-05 2005-07-08 Servier Lab Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2856065B1 (fr) * 2003-06-13 2005-08-19 Servier Lab Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2856064B1 (fr) * 2003-06-13 2005-08-19 Servier Lab Nouveaux derives de benzothiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
AU2004255581A1 (en) 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag Arylamine-substituted quinazolinone compounds
EP1668008A4 (en) 2003-08-28 2009-02-25 Nitromed Inc NITROSED AND NITROSYLATED DIETETIC COMPOUNDS, COMPOSITIONS AND APPLICATION METHODS
US7244843B2 (en) 2003-10-07 2007-07-17 Bristol-Myers Squibb Company Modulators of serotonin receptors
FR2877338B1 (fr) 2004-11-03 2007-01-26 Servier Lab Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2877342B1 (fr) * 2004-11-03 2007-01-26 Servier Lab Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2879201B1 (fr) * 2004-12-10 2007-02-16 Servier Lab Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7238702B2 (en) 2005-02-10 2007-07-03 Bristol-Myers Squibb Company Dihydroquinazolinones as 5HT modulators
AU2006216665A1 (en) 2005-02-24 2006-08-31 Nicox S.A. Nitric oxide enhancing diuretic compounds, compositions and methods of use
GB0507298D0 (en) * 2005-04-11 2005-05-18 Novartis Ag Organic compounds
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
RU2333211C1 (ru) * 2006-11-01 2008-09-10 Институт физиологически активных веществ Российской Академии наук N,n`-замещенные 3, 7-диазабицикло[3.3.1]нонаны, обладающие фармакологической активностью, фармацевтические композиции на их основе и способ их применения
ES2374995T3 (es) 2007-01-03 2012-02-23 Les Laboratoires Servier Compuesto de [1,2,3]-benzotriazinona 3-sustituido para mejorar las respuestas sinápticas glutamatérgicas.
CL2008000119A1 (es) 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
CN101742911A (zh) 2007-05-17 2010-06-16 科泰克斯药品公司 用于增强谷氨酸能突触反应的二取代的酰胺
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
BRPI0823262A2 (pt) 2007-08-10 2013-09-24 Cortex Pharma Inc mÉtodo de tratamento de depressço respiratària e uso de um composto na fabricaÇço de um medicamento para o tratamento de depressço respiratària
FR2933698A1 (fr) 2008-07-09 2010-01-15 Servier Lab Nouveaux derives de benzothiadiazines cycloalkylees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DK2464645T3 (en) 2009-07-27 2017-10-23 Gilead Sciences Inc CONDENSED, HETEROCYCLIC COMPOUNDS AS IRON CHANNEL MODULATORS
FR2955107B1 (fr) * 2010-01-08 2012-03-02 Servier Lab Nouveaux derives thiochromanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2955106B1 (fr) 2010-01-08 2011-12-23 Servier Lab Nouveaux derives de benzothiadiazines cyclopropylees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US8703759B2 (en) 2010-07-02 2014-04-22 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
IT1402905B1 (it) * 2010-11-29 2013-09-27 Univ Degli Studi Modena E Reggio Emilia Derivati di 1,2,4-benzotiadiazin 1,1-diossido, loro preparazione e loro impiego come modulatori allosterici del recettore ampa.
PL2707361T3 (pl) 2011-05-10 2018-01-31 Gilead Sciences Inc Skondensowane związki heterocykliczne stosowane jako modulatory kanału sodowego
NO3175985T3 (is) 2011-07-01 2018-04-28
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
KR102302580B1 (ko) 2013-05-30 2021-09-15 이도르시아 파마슈티컬스 리미티드 Cxcr7 수용체 조절제
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
CN103275016B (zh) * 2013-06-04 2015-03-11 温州医科大学附属第二医院 一种2-取代喹唑啉化合物的合成方法
BR112015031249A2 (pt) 2013-06-13 2017-07-25 Veroscience Llc método de tratamento, método para tratar um distúrbio metabólico ou um elemento chave do mesmo, método para normalizar um ritmo diário de liberação de dopamina no sumn, método para estimular a liberação de dopamina de neurônios dopaminérgicos no sumn de um indivíduo e composição farmacêutica
CN103772296B (zh) * 2013-12-19 2015-06-17 安徽师范大学 一种喹唑啉衍生物的合成方法
CA2963447A1 (en) 2014-12-01 2016-06-09 Actelion Pharmaceuticals Ltd Cxcr7 receptor modulators
JP7574215B2 (ja) 2019-04-29 2024-10-28 ソレント セラピューティクス，エルエルシー ＭＲＧＸ２の阻害薬である３－アミノ－４Ｈ－ベンゾ［ｅ］［１，２，４］チアジアジン１，１－ジオキシド誘導体
EP4031552B1 (en) 2019-09-16 2024-11-06 Takeda Pharmaceutical Company Limited Azole-fused pyridazin-3(2h)-one derivatives
RU2726456C1 (ru) * 2019-10-02 2020-07-14 Общество с ограниченной ответственностью "Научно-исследовательский институт ХимРар" (ООО "НИИ ХимРар") Ингибитор вируса гепатита В (ВГВ)
CN113121470A (zh) * 2021-03-05 2021-07-16 天津理工大学 一种苯并噻二嗪-1,1-二氧化物类化合物的制备方法
EP4642459A2 (en) * 2022-12-30 2025-11-05 Aexon Labs. Inc. Dihydro-quinazoline, -benzothiazine and -benzoxazine derivatives and use thereof as orexin receptors agonists for treating or preventing neurological diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3275625A (en) * 1966-09-27 Derivatives of
NL296964A (is) *
FR1217929A (fr) * 1958-03-03 1960-05-06 Ciba Geigy Procédé de préparation du 1,1-dioxyde de la 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine et de ses sels
GB863474A (en) * 1958-08-13 1961-03-22 Knud Abildgaard Benzothiadiazine derivatives and their preparation
DE1125938B (de) * 1960-02-12 1962-03-22 Thomae Gmbh Dr K Verfahren zur Herstellung von 7-Sulfamyl-3, 4-dihydro-1, 2, 4-benzothiadiazin-1, 1-dioxyden
GB946864A (en) * 1960-05-06 1964-01-15 Knud Abildgaard Method for the production of 3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxides
US3419552A (en) * 1961-04-12 1968-12-31 Lilly Co Eli Preparation of substituted dihydrobenzothiadiazine-1,1-dioxides
CH475269A (de) * 1962-04-19 1969-07-15 Hans Voigt Chem Pharm Fabrik D Verfahren zur Herstellung von 7-Sulfonamido-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
US3351595A (en) * 1962-12-07 1967-11-07 Ciba Geigy Corp Derivatives of 3, 4-dihydro-2h-1, 2, 4-benzothiadiazine-1, 1-dioxide
US3311620A (en) * 1963-05-31 1967-03-28 Stanley C Bell Fused ring benzothiadiazines
US3277086A (en) * 1964-07-07 1966-10-04 American Home Prod 1, 2, 4-benzothiadiazine 1, 1-dioxides having a heterocyclic ring fused to the "b" face thereof
US4184039A (en) * 1977-12-01 1980-01-15 Paul Finkelstein Benzothiadiazine 1, 1-dioxides
EP0636124A1 (fr) * 1992-04-15 1995-02-01 Aventis Pharma S.A. Derives d'acide 3,4-dihydro-2h-1,2,4-benzothiadiazine 1,1-dioxyde-3-carboxylique, leur preparation et les medicaments les contenant
US5488049A (en) * 1993-12-10 1996-01-30 Fidia - Georgetown Institute For The Neuro-Sciences Method of treating learning and memory disorders using benzothiadiazide derivatives as nootropic agents
FR2722502B1 (fr) * 1994-07-12 1996-08-23 Adir Nouveau derive de benzothiadiazine, son procede depreparation et les compositions pharmaceutiques qui le contiennent
ATE478672T1 (de) * 1996-01-29 2010-09-15 Univ California Methode zur behandlung sexueller fehlfunktionen
AU4345297A (en) * 1996-09-17 1998-04-14 Regents Of The University Of California, The Benzothiadiazide derivatives and their use as allosteric up-modulators of the ampa receptor

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1308317C (zh) * 2004-01-26 2007-04-04 瑟维尔实验室 新的氟化苯并噻二嗪化合物，它们的制备方法和含有它们的药物组合物
CN102361860A (zh) * 2009-03-20 2012-02-22 瑟维尔实验室 用作ampa和nmda受体调节剂的苯并硫杂二氮杂*衍生物
CN102361860B (zh) * 2009-03-20 2014-09-10 瑟维尔实验室 用作ampa和nmda受体调节剂的苯并硫杂二氮杂*衍生物
CN102958919A (zh) * 2010-07-02 2013-03-06 霍夫曼-拉罗奇有限公司 新的四氢喹啉衍生物
CN103153973A (zh) * 2010-09-16 2013-06-12 瑟维尔实验室 二氢苯并氧硫氮杂*衍生物、其制备方法、包含此类化合物的药用组合物以及它们作为ampa受体调节剂的用途
CN102977054A (zh) * 2012-12-12 2013-03-20 中国药科大学 一类选择性α2A受体激动剂的治疗阿尔茨海默病用途
CN103319381A (zh) * 2013-06-14 2013-09-25 湖州康企药业有限公司 一种高纯度精磺胺的制备方法
CN103319381B (zh) * 2013-06-14 2014-08-27 湖州康企药业有限公司 一种高纯度精磺胺的制备方法
CN105294599A (zh) * 2015-09-17 2016-02-03 三峡大学 一种噻二嗪类化合物及其不对称的合成方法
CN106946920A (zh) * 2017-04-05 2017-07-14 泰力特医药（湖北）有限公司 一种4‑氨基苯硼酸衍生物的制备方法
WO2020253860A1 (zh) * 2019-06-21 2020-12-24 江苏豪森药业集团有限公司 芳基磷氧化物类衍生物抑制剂、其制备方法和应用
CN112469713A (zh) * 2019-06-21 2021-03-09 江苏豪森药业集团有限公司 芳基磷氧化物类衍生物抑制剂、其制备方法和应用
CN112469713B (zh) * 2019-06-21 2023-09-01 江苏豪森药业集团有限公司 芳基磷氧化物类衍生物抑制剂、其制备方法和应用
CN111100042A (zh) * 2019-11-18 2020-05-05 苏州诚和医药化学有限公司 一种2-甲氧基-5-磺酰胺基苯甲酸的制备方法
CN111100042B (zh) * 2019-11-18 2022-05-31 苏州诚和医药化学有限公司 一种2-甲氧基-5-磺酰胺基苯甲酸的制备方法
CN111018750A (zh) * 2019-12-19 2020-04-17 苏州诚和医药化学有限公司 一种2,3-二甲氧基-5-磺酰胺基苯甲酸的制备新方法
CN111018750B (zh) * 2019-12-19 2022-05-27 苏州诚和医药化学有限公司 一种2,3-二甲氧基-5-磺酰胺基苯甲酸的制备新方法

Also Published As

Publication number Publication date
RU2214405C2 (ru) 2003-10-20
NO20004121L (no) 2000-10-17
EP1071426A2 (en) 2001-01-31
EE200000468A (et) 2002-04-15
HUP0101280A2 (hu) 2001-10-28
NO20004121D0 (no) 2000-08-17
PL342843A1 (en) 2001-07-16
SK11892000A3 (sk) 2001-02-12
AU2512399A (en) 1999-09-06
WO1999042456A3 (en) 1999-10-07
ZA991301B (en) 1999-09-13
IL137720A0 (en) 2001-10-31
TR200002427T2 (tr) 2001-01-22
AU751384B2 (en) 2002-08-15
NZ506251A (en) 2003-01-31
HUP0101280A3 (en) 2003-02-28
WO1999042456A2 (en) 1999-08-26
IS5581A (is) 2000-08-04
JP2002504481A (ja) 2002-02-12
CA2320354A1 (en) 1999-08-26

Similar Documents

Publication Publication Date Title
CN1293665A (zh) 新化合物及其用作阳性ampa受体调节剂
CN1237060C (zh) 用作α1A/B肾上腺素能受体拮抗剂的喹唑酮衍生物
US6498177B2 (en) Indole and benzothiazole derivatives
CN1191249C (zh) 用于治疗、特别是治疗良性前列腺增生的喹啉和喹唑啉化合物
CN1133625C (zh) 喹唑啉衍生物
CN1052004C (zh) 杂环化合物及其制备和应用
US6943159B1 (en) Compounds and their use as positive AMPA receptor modulators
CN1413210A (zh) 用于治疗炎症、自身免疫性疾病和呼吸系统疾病的vla－4依赖性细胞结合的非肽基抑制剂
CN1535272A (zh) 用于抗菌剂的二环含氮杂环
CN1231664A (zh) 调整内皮肽活性的磺酰胺及其衍生物
CN1110685A (zh) 含氮的螺环
CA2684470A1 (en) Pyrimidine derivatives
CN1784409A (zh) 具有crf活性的稠合的嘧啶衍生物
MX2013009627A (es) Derivados de diaminopirimidina y procesos para su preparacion.
CN1914204A (zh) 萘啶衍生物及其作为毒蕈碱性受体调节剂的用途
CN1180351A (zh) 作为内皮素拮抗剂的苯并噻嗪二氧化物
KR100802856B1 (ko) 아릴아민-치환된 퀴나졸린온 화합물
CN1780831A (zh) 作为腺苷受体配体的2－咪唑－苯并噻唑
HK1036055A (en) Novel compounds and their use as positive ampa receptor modulators
CN1878758A (zh) Crf拮抗剂和二环杂环化合物
CN1845918A (zh) 可用作电压－门控离子通道调节剂的嘧啶
MXPA00008128A (en) Novel compounds and their use as positive ampa receptor modulators
CZ20002896A3 (cs) Nové sloučeniny a jejich použití jako pozitivních modulátorů AMPA receptoru

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1036055

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication